BSE - Delayed Quote INR

Novartis India Limited (NOVARTIND.BO)

973.15
+18.60
+(1.95%)
At close: May 23 at 3:41:43 PM GMT+5:30
Loading Chart for NOVARTIND.BO
  • Previous Close 954.55
  • Open 960.00
  • Bid 967.05 x --
  • Ask 973.00 x --
  • Day's Range 957.25 - 988.00
  • 52 Week Range 744.95 - 1,248.00
  • Volume 21,419
  • Avg. Volume 16,524
  • Market Cap (intraday) 24.028B
  • Beta (5Y Monthly) -0.01
  • PE Ratio (TTM) 23.81
  • EPS (TTM) 40.87
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield 25.00 (2.57%)
  • Ex-Dividend Date Jul 23, 2025
  • 1y Target Est --

Novartis India Limited operates as a healthcare company in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neurosciences products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is based in Mumbai, India. The company is a subsidiary of Novartis AG.

www.novartis.in

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NOVARTIND.BO

View More

Performance Overview: NOVARTIND.BO

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

NOVARTIND.BO
5.80%
S&P BSE SENSEX (^BSESN)
4.58%

1-Year Return

NOVARTIND.BO
10.08%
S&P BSE SENSEX (^BSESN)
8.36%

3-Year Return

NOVARTIND.BO
84.25%
S&P BSE SENSEX (^BSESN)
50.53%

5-Year Return

NOVARTIND.BO
97.28%
S&P BSE SENSEX (^BSESN)
166.43%

Compare To: NOVARTIND.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NOVARTIND.BO

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    24.03B

  • Enterprise Value

    17.59B

  • Trailing P/E

    23.81

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.74

  • Price/Book (mrq)

    3.06

  • Enterprise Value/Revenue

    4.94

  • Enterprise Value/EBITDA

    13.19

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.32%

  • Return on Assets (ttm)

    6.32%

  • Return on Equity (ttm)

    13.19%

  • Revenue (ttm)

    3.56B

  • Net Income Avi to Common (ttm)

    1.01B

  • Diluted EPS (ttm)

    40.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.48B

  • Total Debt/Equity (mrq)

    0.64%

  • Levered Free Cash Flow (ttm)

    625.72M

Research Analysis: NOVARTIND.BO

View More

Company Insights: NOVARTIND.BO

Research Reports: NOVARTIND.BO

View More

People Also Watch